Disease progression prediction and therapeutic drug target discovery for Coronavirus disease 2019(COVID-19)are particularly important,as there is still no effective strategy for severe COVID-19 patient treatment.Herei...Disease progression prediction and therapeutic drug target discovery for Coronavirus disease 2019(COVID-19)are particularly important,as there is still no effective strategy for severe COVID-19 patient treatment.Herein,we performed multi-platform omics analysis of serial plasma and urine samples collected from patients during the course of COVID-19.Integrative analyses of these omics data revealed several potential therapeutic targets,such as ANXA1 and CLEC3B.Molecular changes in plasma indicated dysregulation of macrophage and suppression of T cell functions in severe patients compared to those in non-severe patients.Further,we chose 25 important molecular signatures as potential biomarkers for the prediction of disease severity.The prediction power was validated using corresponding urine samples and plasma samples from new COVID-19 patient cohort,with AUC reached to 0.904 and 0.988,respectively.In conclusion,our omics data proposed not only potential therapeutic targets,but also biomarkers for understanding the pathogenesis of severe COVID-19.展开更多
基金This work is supported by the grants from The National Key Research and Development Program of China(2018YFC1200100 to JC2L)National Science and Technology Major Project(2018ZX10301403 to JCZ.)+5 种基金the emergency grants for prevention and control of SARS-CoV-2 of Ministry of Science and Technology of Guangdong province(2020A111128008,2020B111112003,2018B020207013,2020B111108001 and 2020B1111320003 to JCZ,2020B1111330001 to NZ.)The National Program on Key Basic Research Project(2017YFC0906702 to Y.W.)National Key Technology R&D Program(2018YFC1311900 to N2.)Guangdong Science and Technology Foundation(2019B030316028,2020A1515010911 to NZ.)Guangzhou Medical University High-level University Innovation Team Training Program(Guangzhou Medical University released[2017]No.159 to JCZ and JX2.)111 project(D18010 to JCZI ).We thank the patients who took part in this study.
文摘Disease progression prediction and therapeutic drug target discovery for Coronavirus disease 2019(COVID-19)are particularly important,as there is still no effective strategy for severe COVID-19 patient treatment.Herein,we performed multi-platform omics analysis of serial plasma and urine samples collected from patients during the course of COVID-19.Integrative analyses of these omics data revealed several potential therapeutic targets,such as ANXA1 and CLEC3B.Molecular changes in plasma indicated dysregulation of macrophage and suppression of T cell functions in severe patients compared to those in non-severe patients.Further,we chose 25 important molecular signatures as potential biomarkers for the prediction of disease severity.The prediction power was validated using corresponding urine samples and plasma samples from new COVID-19 patient cohort,with AUC reached to 0.904 and 0.988,respectively.In conclusion,our omics data proposed not only potential therapeutic targets,but also biomarkers for understanding the pathogenesis of severe COVID-19.
